DEST.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 16:55):

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom...

Stats
Dagens volum	254 775
Gjennomsnittsvolum	546 210
Markedsverdi	17.53M
EPS	£0 ( 2024-04-10 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-3.07
ATR14	£0.232 (1.26%)

Destiny Pharma PLC Korrelasjon

10 Mest positive korrelasjoner
WINE.L	0.9
GHT.L	0.889
INDV.L	0.883
DPEU.L	0.873
ONC.L	0.859
MCM.L	0.853
RMMC.L	0.842
UPGS.L	0.834
RWS.L	0.833
DGN.L	0.829

10 Mest negative korrelasjoner
CMET.L	-0.851
PEN.L	-0.827
CAMB.L	-0.818
EUZ.L	-0.804

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Destiny Pharma PLC Økonomi

Annual	2023
Omsetning:	£831 552
Bruttogevinst:	£831 552 (100.00 %)
EPS:	£-0.0624

FY	2023
Omsetning:	£831 552
Bruttogevinst:	£831 552 (100.00 %)
EPS:	£-0.0624

FY	2022
Omsetning:	£154 499
Bruttogevinst:	£142 171 (92.02 %)
EPS:	£-0.0926

FY	2021
Omsetning:	£0.00
Bruttogevinst:	£0.00 (0.00 %)
EPS:	£-0.0890

Financial Reports:

No articles found.

Destiny Pharma PLC

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.